Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$67.82 USD

67.82
1,140,451

-0.09 (-0.13%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $67.85 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Genomic Health's (GHDX) Oncotype DX GPS Test Data Positive

by Zacks Equity Research

Genomic Health, Inc. (GHDX), a global cancer company, recently presented positive results for its Oncotype DX Genomic Prostate Score (GPS) test.

    Zacks Equity Research

    Teleflex to Introduce Arrow AC3 Optimus at EuroPCR, Paris

    by Zacks Equity Research

    Teleflex Inc. (TFX) announced plans to introduce Arrow AC3 Optimus Intra-Aortic Balloon Pump at the European Association for Percutaneous Cardiovascular Interventions Course (EuroPCR) in Paris during May 16--19.

      Zacks Equity Research

      Thermo Fisher (TMO) to Buy Patheon, Expand in Biopharma

      by Zacks Equity Research

      Thermo Fisher Scientific Inc. (TMO), a leading scientific instrument maker, recently agreed to acquire Netherlands-based Patheon N.V.

        Zacks Equity Research

        Medtronic ICMs Detect High Rate of AF in Undiagnosed Patients

        by Zacks Equity Research

        Medical device major Medtronic plc (MDT) recently unveiled results from a new clinical study evaluating Insertable Cardiac Monitors (ICMs).

          Zacks Equity Research

          CR Bard (BCR) Hits a 52-Week High: What's Driving the Stock?

          by Zacks Equity Research

          Shares of CR Bard (BCR), also known as Bard, rallied to a new 52-week high of $309.16 on May 12. Let us take a look at the key catalysts driving the stock's performance.

            Zacks Equity Research

            Hologic (HOLX) Tops Q2 Earnings & Sales, Raises 2017 View

            by Zacks Equity Research

            Hologic Inc. (HOLX) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 50 cents, up 6.4% year over year.

              Zacks Equity Research

              Varian ProBeam Proton System Gets Okayed by Shonin in Japan

              by Zacks Equity Research

              Varian Medical Systems, Inc. (VAR) recently announced that its flagship ProBeam system for proton therapy has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW)

                Zacks Equity Research

                Inogen (INGN) Beats Earnings and Revenue Estimates in Q1

                by Zacks Equity Research

                Inogen (INGN) reported a stellar first quarter of 2017, beating the Zacks Consensus Estimate for both the counts. The company witnessed solid growth in revenues and adjusted earnings on a year-over-year basis.

                  Zacks Equity Research

                  STERIS (STE) Tops Q4 Earnings & Revenues, Issues '18 View

                  by Zacks Equity Research

                  STERIS Plc (STE) reported fourth-quarter fiscal 2017 adjusted earnings per share (EPS) of $1.11, up 23.3% from the year-ago quarter.

                    Zacks Equity Research

                    Abiomed (ABMD) Q4 Earnings Meet, Revenues Beat Estimates

                    by Zacks Equity Research

                    Abiomed Inc. (ABMD), a leading developer, manufacturer and marketer of medical products, reported fourth-quarter fiscal 2017 earnings of 33 cents per share, which were in line with the Zacks Consensus Estimate.

                      Zacks Equity Research

                      Penumbra (PEN) Q1 Loss Wider than Expected, View Intact

                      by Zacks Equity Research

                      Penumbra, Inc. (PEN), that went public in Sep 2015, reported first-quarter 2017 loss of 10 cents per share, comparing unfavorably with earnings of 7 cents year over year.

                        Zacks Equity Research

                        PetMed (PETS) Beats Earnings, Revenue Estimates in Q4

                        by Zacks Equity Research

                        PetMed Express, Inc. (PETS) announced earnings per share of 37 cents for the fourth quarter of fiscal 2017, up 37% from the year-ago quarter's 27 cents.

                          Zacks Equity Research

                          Henry Schein (HSIC) Tops Q1 Earnings, Reaffirms '17 View

                          by Zacks Equity Research

                          Henry Schein, Inc. (HSIC) reported adjusted earnings per share (EPS) of $1.76 in the first quarter of 2017, up 24.8% year over year.

                            Zacks Equity Research

                            Haemonetics (HAE) Tops Q4 Earnings, Sales, Issues 2018 View

                            by Zacks Equity Research

                            Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2017, up 5.4% year over year.

                              Zacks Equity Research

                              DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q1

                              by Zacks Equity Research

                              DENTSPLY SIRONA Inc. (XRAY) reported adjusted earnings per share of 49 cents in the first quarter of 2017, missing the Zacks Consensus Estimate by 2 cents.

                                Zacks Equity Research

                                Integer (ITGR) Q1 Earnings Miss, Revenues Beat Estimates

                                by Zacks Equity Research

                                Integer Holdings Corporation (ITGR) reported adjusted earnings of 41 cents per share in the first quarter of 2017, a penny down on a year-over-year basis.

                                  Zacks Equity Research

                                  Phibro (PAHC) Posts In Line Earnings in Q3, Revises View

                                  by Zacks Equity Research

                                  Phibro Animal Health Corporation (PAHC) reported adjusted earnings per share (EPS) of 37 cents in the third quarter of fiscal 2017, down 7.5% year over year.

                                    Zacks Equity Research

                                    Align Technology Invisalign Sales Strong, Currency Woes Stay

                                    by Zacks Equity Research

                                    On May 5, we issued an updated research report on Align Technology (ALGN), which manufactures a system of clear aligner therapy.

                                      Zacks Equity Research

                                      Qiagen Banks on Molecular Diagnostic amid Currency Woes

                                      by Zacks Equity Research

                                      On May 4, we issued an updated research report on leading molecular diagnostic company, Qiagen N.V. (QGEN).

                                        Zacks Equity Research

                                        CVS Down on Weak Earnings, Pharmacy Services Remains Strong

                                        by Zacks Equity Research

                                        On May 5, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS).

                                          Zacks Equity Research

                                          Abiomed (ABMD) Q4 Earnings Meet, Revenues Beat Estimates

                                          by Zacks Equity Research

                                          Abiomed posted a promising fourth quarter of fiscal 2017, with revenues beating the Zacks Consensus Estimate and earnings meeting the mark.

                                            Zacks Equity Research

                                            VWR Corp (VWR) Beats on Q1 Earnings, Awaits Merger Closure

                                            by Zacks Equity Research

                                            VWR Corporation (VWR) reported first-quarter 2017 adjusted earnings per share (EPS) of 44 cents, reflecting a 10% rise from the year-ago quarter.

                                              Zacks Equity Research

                                              BioScrip (BIOS) Q1 Loss Narrower than Expected, Sales Miss

                                              by Zacks Equity Research

                                              BioScrip, Inc. (BIOS) reported net loss from continuing operations of $19.4 million or a loss of 18 cents per share in the first quarter of 2017 compared with net loss of $9.5 million or a loss of 17 cents a year ago.

                                                Zacks Equity Research

                                                Allscripts (MDRX) Beats on Q1 Earnings, Revenues In Line

                                                by Zacks Equity Research

                                                Allscripts Healthcare Solutions, Inc. (MDRX) reported first-quarter 2017 earnings of 10 cents per share, beating the Zacks Consensus Estimate by a penny.

                                                  Zacks Equity Research

                                                  Omnicell (OMCL) Q1 Loss Narrower than Expected, Revenues Lag

                                                  by Zacks Equity Research

                                                  Omnicell, Inc. (OMCL) reported a loss per share of 29 cents in first-quarter 2017, reflecting a deterioration from the year-ago loss of a penny.